Novel Breakthrough for treatment of obesity

3 conundrums in obesity management are:
  1. Need to promote hunger suppression and food avoidance;  
  2. Enhance satiety and fullness:   
  3. Stop binge and or nighttime eating.  
Numerous studies have documented that medications which increase brain serotonin (5-HT) are effective anorectic agents which help obese patients lose weight and also decrease craving for sweets and carbohydrates. 

Evidence from other studies also indicate that increases in brain 5-HT may help decrease craving for alcohol and cocaine.  

It's all the same addictive behavior:  
  1. Eating 
  2. Sex 
  3. Compulsive gambling 
  4. Drug and or alcohol addicition.  
A novel mediciation i.e.,  5-hydroxy-L-tryptophan, abbreviated 5-HTP, is the immediate precursor of serotonin (5-HT). When administered in combination with an inhibitor of peripheral decarboxylase such as carbidopa, 5-HTP increases brain serotonin.  Without being combined with the carboxylase inhibitor, straight 5-HT is less effective.   Increases in synaptic 5-HT decreases the firing rate of 5-HT neurons via stimulation of inhibitory 5-HT1a receptors located on the cell bodies in the raphe.  This serves as a negative feedback loop.  

The clinically available beta adreneric receptor antagonist medication pindolol (normally used for B/P control) ironically also acts as a  5-HT1a antagonist, and can be used to increase the ability of 5-HTP to increase brain 5-HT. Previous studies with 5-HTP used doses exceeding 50 mg per day. When 5-HTP was used in combination with carbidopa, the dose of carbidopa was in excess of 50 mg per day. One novel aspect of the invention are the doses of the 5-HTP and carbidopa: much lower daily doses than have been used before are effective in decreasing appetite, decreasing craving for food and for promoting weight loss. The second novel aspect of the invention relates to the concurrent use of pindolol along with the 5-HTP/Carbidopa, which enhances the effectiveness of the 5-HTP/Carbidopa combination.

Trimcare is pleased to announce our medically supervised approach has incorporated all these ideas of increasing Norepinephrine with our novel appetite suppressant formulations.  Additionally, by increasing Seratonin, we address the issue of fullness and satiety.  Finally, with our off-label use of a novel migraine medication we have addressed the issue of binge or nighttime eating.

Trimcare weight loss.  Leading the fight in Las Vegas against obesity.  Medically supervised by a board certified Bariatrician i.e., Dr. Ivan L Goldsmith and his team at their nationally recognized centers of excellence;  Trimcare Weight Loss.    (conveniently located in central Las Vegas and Henderson). 

Incidentally, ask about our new CLA (over the cournter (conjugated linoleic acid) that has been found to be extremely helpful in preventing weight regain. 
 

No comments:

Post a Comment